Loading
companiesCompany
Altay Therapeutics
Altay Therapeutics is developing small-molecule drugs for chronic liver disease, including the scarring that leads to liver cancer and liver cancer itself.
Overview
Altay Therapeutics develops oral small molecules against transcription-factor-driven pathways in liver fibrosis and hepatocellular carcinoma. Its YC profile reports preclinical mouse data showing reduction and partial reversal of fibrosis, and a plan to reach phase 1. The co-founder led early development of pirfenidone, the first approved drug for lung fibrosis. Oncology is one of two stated indications; programmes are preclinical as far as public sources show. Included because liver cancer is an explicit target.
Headquarters
South San Francisco, CA, US
Funding
All startupsStartupYC W20
Investors
Type
Stage
Startup · Y Combinator Winter 2020
Website
Similar pages
- CompanyAlixia
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyHumane Genomics
Shares Y Combinator, Hepatocellular carcinoma and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.